Northland Securities analyst Suraj Kalia maintained a Hold rating on Obalon Therapeutics Inc (OBLN) today and set a price target of $2. The company’s shares opened today at $2.29, close to its 52-week low of $1.46.
Kalia commented:
“We are tweaking our models to reflect “our best interpretation” of company commentary. FY19 guidance will be provided on the Q4 call sometime in February. Overall, our fundamental concerns on the story remain.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 8.0% and a 53.7% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Apollo Endosurgery Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Obalon Therapeutics Inc with a $2.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.19 and a one-year low of $1.46. Currently, Obalon Therapeutics Inc has an average volume of 245.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated.
